Capricor Therapeutics, Inc. $CAPR Stock: Oppenheimer & Co. Inc. Raises Stake

Oppenheimer & Co. Inc. lifted its holdings in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) by 169.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 203,781 shares of the biotechnology company’s stock after purchasing an additional 128,067 shares during the quarter. Oppenheimer & Co. Inc. owned 0.35% of Capricor Therapeutics worth $1,930,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Montanova Capital LLC increased its position in shares of Capricor Therapeutics by 7.2% in the second quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company’s stock worth $98,554,000 after purchasing an additional 274,184 shares during the last quarter. Bank of America Corp DE lifted its position in Capricor Therapeutics by 672.0% during the first quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company’s stock valued at $12,631,000 after purchasing an additional 361,664 shares during the last quarter. Walleye Capital LLC bought a new stake in Capricor Therapeutics during the first quarter valued at approximately $5,397,000. Bank of New York Mellon Corp bought a new stake in Capricor Therapeutics during the second quarter valued at approximately $3,895,000. Finally, Ally Bridge Group NY LLC bought a new stake in Capricor Therapeutics during the first quarter valued at approximately $3,463,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on CAPR shares. Cantor Fitzgerald raised shares of Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Friday, August 14th. JonesTrading cut shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, July 31st. B. Riley Financial raised shares of Capricor Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $5.00 to $21.00 in a report on Monday, September 14th. LADENBURG THALM/SH SH downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, July 30th. Finally, HC Wainwright lowered shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, July 27th. Four analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $30.25.

Capricor Therapeutics Price Performance

Shares of NASDAQ CAPR opened at $6.38 on Friday. Capricor Therapeutics, Inc. has a one year low of $2.96 and a one year high of $40.37. The firm’s 50 day simple moving average is $8.06 and its two-hundred day simple moving average is $20.60. The stock has a market capitalization of $370.93 million, a P/E ratio of -2.60 and a beta of 0.61.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.11). As a group, equities analysts expect that Capricor Therapeutics, Inc. will post -1.71 earnings per share for the current fiscal year.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company’s research and development programs are designed to address conditions involving muscle degeneration, inflammation and tissue damage.

Capricor’s lead investigational product is deramiocel, also known as CAP-1002, an allogeneic cardiac-derived cell therapy being developed for Duchenne muscular dystrophy. The company has also developed an exosome-based technology platform intended to support the delivery of therapeutic proteins, nucleic acids and other biological materials.

Founded in 2005, Capricor is headquartered in San Diego, California, and conducts its development activities primarily in the United States while working with research, clinical and commercial partners.